RxDoctor Payments Data

Steven Chooljian, MD

Internal Medicine · Fresno, CANPI 1245250232

Payments from drug & device makers

$8,341in general payments, 2019–2025

Across 473 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$823
  • Novartis$662
  • AstraZeneca$647
  • Novo Nordisk$488
  • Kowa Pharmaceuticals America, Inc.$418
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,341100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,341 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$227,670
Medicare patients
324
Services billed
3,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$178,036
OzempicSemaglutide98$103,316
MounjaroTirzepatide45$44,831
MyrbetriqMirabegron44$41,846
VascepaIcosapent Ethyl72$39,700
Repatha SureclickEvolocumab45$33,095
TrulicityDulaglutide29$31,013
FarxigaDapagliflozin Propanediol29$26,044
SynthroidLevothyroxine Sodium231$24,649
XareltoRivaroxaban30$22,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$20,122
JardianceEmpagliflozin19$18,971
TrintellixVortioxetine Hydrobromide44$18,813
LinzessLinaclotide15$17,160
EdarbiAzilsartan Medoxomil34$15,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Dilantin$321$184,373264 claims
Novo NordiskOzempic, Rybelsus$488$115,521111 claims
Lilly USA, LLCMounjaro, Trulicity$162$75,84574 claims
Astellas Pharma US IncMyrbetriq$68$41,84644 claims
AbbVieSynthroid, Linzess$1,169$41,809246 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$258$40,15251 claims
AstraZenecaFarxiga$647$26,04429 claims
Johnson & JohnsonXarelto$333$22,08330 claims
GSKTrelegy Ellipta$172$20,12218 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$185$18,81344 claims
Arbor Pharmaceuticals, Inc.Edarbi$38$15,96934 claims
Kowa Pharmaceuticals America, Inc.Livalo$418$10,52727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →